Associations of radiotherapy receipt with lung cancer risk by histological subtype among breast cancer survivors in the United States
International Journal of Cancer · 2025
DOI: 10.1002/ijc.35257 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Chenxi Jiang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Surveillance & Health Equity Science, American Cancer Society, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Lung Neoplasms, Cancer Survivors, Neoplasms, Second Primary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Intramural Research Department of the American Cancer Society.
Abstract (Originalsprache)
Radiotherapy for breast cancer has been associated with an increased risk of secondary malignancies, including primary lung cancer. Whether this association varies by histological subtype of lung cancer remains unknown. Based on the data from 12 Surveillance, Epidemiology, and End Results registries, we examined the association between radiotherapy receipt and the risk of subtype‐specific subsequent primary lung cancer (SPLC) among female first primary breast cancer cases diagnosed between ages 20 and 84 from 1992 to 2020. More than half (53%) of the 550,007 breast cancer survivors identified had undergone radiotherapy as part of their initial breast cancer treatment. Over an average follow‐up of 9.7 years, 8014 survivors developed SPLCs. For small‐cell carcinoma, the standardized incidence ratio (SIR) compared with the general population was higher for survivors who received radiotherapy (SIR = 1.15, 95% confidence interval [CI] = 1.06–1.25) but similar for those who did not receive radiotherapy (SIR = 1.00, 95% CI = 0.91–1.09), with the difference in SIRs being statistically significant ( p = .003). Similar associations were found for squamous cell carcinoma (SIR yes = 1.16, 95% CI = 1.08–1.24 vs. SIR no/unknown = 1.06, 95% CI = 0.98–1.15; p = .07). The increased risks were confined to ipsilateral SPLC, with the greatest SIRs for small‐cell carcinoma occurring 5–10 years since breast cancer diagnosis (SIR = 1.83, 95% CI = 1.53–2.19) and for squamous cell carcinoma with a latency of 10 years or more (SIR = 1.64, 95% CI = 1.42–1.88). In contrast, the risk of developing adenocarcinoma did not vary by radiotherapy receipt (SIR yes = 1.23, 95% CI = 1.18–1.28 vs. SIR no/unknown = 1.17, 95% CI = 1.12–1.22; p = .18), indicating additional risk factors in play. The findings suggest a distinct carcinogenic pathway of radiation‐induced lung cancer across histological subtypes and may inform risk‐stratified surveillance guidelines for SPLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Surveillance & Health Equity Science, American Cancer Society, Atlanta, Georgia, USA.
- Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Brigham and Women's Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Chenxi Jiang, Ahmedin Jemal, Hyuna Sung
Förderung
- Intramural Research Department of the American Cancer Society
Zitieren
APA
Jiang, C., Freedman, R. A., Punglia, R. S., Jemal, A., & Sung, H. (2025). Associations of radiotherapy receipt with lung cancer risk by histological subtype among breast cancer survivors in the United States. International Journal of Cancer. https://doi.org/10.1002/ijc.35257
Vancouver
Jiang C, Freedman RA, Punglia RS, Jemal A, Sung H. Associations of radiotherapy receipt with lung cancer risk by histological subtype among breast cancer survivors in the United States. International Journal of Cancer. 2025. doi:10.1002/ijc.35257
BibTeX
@article{Jiang2025,
author = {Jiang, Chenxi and Freedman, Rachel A and Punglia, Rinaa S and Jemal, Ahmedin and Sung, Hyuna},
title = {Associations of radiotherapy receipt with lung cancer risk by histological subtype among breast cancer survivors in the United States},
journal = {International Journal of Cancer},
year = {2025},
doi = {10.1002/ijc.35257}
}
EUVIMED